{
    "clinical_study": {
        "@rank": "144599", 
        "acronym": "GemTax", 
        "arm_group": {
            "arm_group_label": "Combination therapy", 
            "arm_group_type": "Experimental", 
            "description": "Dose Level\\Docetaxel IV\\ Gemcitabine IV\\Vorinostat PO\\Pegfilgrastim 1\\75 mg/m2\\900 mg/m2\\300 mg once daily\\6 mg on day 9 2\\75 mg/m2\\900 mg/m2\\200 mg twice daily\\6 mg on day 9 3\\75 mg/m2\\900 mg/m2\\300 mg twice daily\\6 mg on day 9 4\\75 mg/m2\\900 mg/m2\\400 mg twice daily\\6 mg on day 9"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study\n      designed to determine the safety, tolerability, and  recommended dose of the combination.\n\n      During the Phase 2 portion of the study, we will assess progression-free survival (PFS),\n      overall survival (OS),overall response rate (ORR), correlative endpoints, DNA methylation\n      measured by microarray, and expression level of the genes as measured by microarray"
        }, 
        "brief_title": "Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "detailed_description": {
            "textblock": "Phase 1b\n\n        -  To determine the dose of vorinostat that can be safely combined with gemcitabine and\n           docetaxel in patients with advanced sarcomas.\n\n        -  To characterize the Pharmacokinetics (PK) and Pharmacodynamics (PD) of vorinostat when\n           combined with gemcitabine and docetaxel in patients with advanced sarcomas.\n\n      Phase 2\n\n        -  To determine the safety and efficacy of gemcitabine and docetaxel in combination with\n           vorinostat in patients with advanced sarcomas. The hypothesis is that gemcitabine and\n           docetaxel + vorinostat will be safe and will improve the 6-months progression-free\n           rates (PFR) of the combination by 20% (from 20% to 40%).\n\n        -  To determine the objective response rate, progression-free, and overall survival of\n           patients with advanced sarcomas treated with gemcitabine and docetaxel + vorinostat;\n\n        -  To develop a predictive molecular signature of response to treatment in advanced\n           sarcomas."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed soft tissue sarcoma with evidence of\n             metastatic or unresectable disease.\n\n          -  Patients must have measurable disease by RECIST 1.1.\n\n          -  Up to 32 prior cytotoxic chemotherapy regimens in the metastatic setting are allowed.\n             Adjuvant chemotherapy or targeted therapy will not be considered a prior line of\n             treatment.\n\n          -  Age \u226518 years.\n\n          -  ECOG performance status \u22642 (Karnofsky \u226560%).\n\n          -  Life expectancy of greater than 12 weeks.\n\n          -  Patients must have normal organ and marrow function as defined below:\n\n               -  leukocytes \u22653,000/\u00b5L\n\n               -  absolute neutrophil count \u22651,500/\u00b5L\n\n               -  platelets \u2265100,000/\u00b5L\n\n               -  total bilirubin within normal institutional limits\n\n               -  AST(SGOT)/ALT(SGPT) \u22641.5 X institutional upper limit of normal (ULN)\n\n               -  creatinine \u22641.5 X institutional upper limit of normal (ULN)\n\n          -  Peripheral neuropathy, if present, should be \u2264grade 1.\n\n          -  Women of Child bearing potential MUST use contraceptives.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  The following specific histologic subtypes of soft tissue sarcomas will be excluded:\n             GIST, Kaposi's sarcoma, mesothelioma, dermatofibrosarcoma, chordoma, alveolar\n             soft-part sarcoma. Also, all bone sarcomas are excluded including Ewing's sarcoma,\n             osteosarcoma, GIST, low grade chondrosarcoma, and chordoma.\n\n          -  Patients who have had treatment with chemotherapy or radiotherapy within 4 weeks (6\n             weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who\n             have not recovered from adverse events due to agents administered more than 4 weeks\n             earlier.\n\n          -  Patients who are receiving any other investigational agents.\n\n          -  Patients with known brain metastases.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to gemcitabine, docetaxel, vorinostat, or G-CSF.\n\n          -  Patients who have received and progressed on the combination of gemcitabine and\n             docetaxel in the metastatic setting.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Pregnant and breastfeeding women\n\n          -  Patients taking concomitant HDAC inhibitors.\n\n          -  HIV-positive patients on combination antiretroviral treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "67", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879085", 
            "org_study_id": "UPCI# 12-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combination therapy", 
                "description": "75 mg/m2 IV over 60 minutes on day 8 every 21 days (1 cycle).", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "description": "given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, Gem will be given over 67.5 minutes at 10 mg/m2/min.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "description": "will be given orally at the specified dose levels (Table 2) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle).", 
                "intervention_name": "Vorinostat", 
                "intervention_type": "Drug", 
                "other_name": "Zolinza"
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "description": "Administered on day 9 subcutaneously at 6 mg.", 
                "intervention_name": "Pegfilgrastim", 
                "intervention_type": "Drug", 
                "other_name": "Neulasta"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Vorinostat", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "advanced", 
            "metastatic", 
            "unresectable", 
            "soft", 
            "tissue", 
            "sarcomas"
        ], 
        "lastchanged_date": "December 31, 2013", 
        "location": [
            {
                "contact": {
                    "email": "santchawla@sarcomaoncology.com", 
                    "last_name": "Sant Chawla, MD", 
                    "phone": "310-552-9999"
                }, 
                "contact_backup": {
                    "email": "vchua@sarcomaoncology.com", 
                    "last_name": "Victoria Chua", 
                    "phone": "(310) 552-9999"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90403"
                    }, 
                    "name": "Sarcoma Oncology Center"
                }, 
                "investigator": {
                    "last_name": "Sant Chawla, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "tawbihx@upmc.edu", 
                    "last_name": "Hussein Tawbi, MD", 
                    "phone": "412-648-6466"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "Hillman Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Hussein Tawbi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma", 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Hussein Tawbi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the dose of vorinostat that can be safely combined with gemcitabine and docetaxel in patients with advanced sarcomas", 
                "measure": "For phase 1 portion: To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination.", 
                "safety_issue": "Yes", 
                "time_frame": "5 years or until disease progression/survival"
            }, 
            {
                "description": "To determine the safety and efficacy of gemcitabine and docetaxel in combination with vorinostat in patients with advanced sarcomas using the Phase 2 recommended dose (RP2D).", 
                "measure": "For phase 2 portion: Six-month progression-free survival rate (PFR).", 
                "safety_issue": "Yes", 
                "time_frame": "six months progression-free survival"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879085"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Hussein Tawbi", 
            "investigator_title": "Assistant Professor of Medicine, Clinical & Translational Science", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination. Six-month progression-free survival rate (PFR).", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years or until disease progression/survival"
            }, 
            {
                "description": "To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination. Six-month progression-free survival rate (PFR).", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years or until disease progression/survival"
            }, 
            {
                "description": "To determine the safety, tolerability, and Phase 2 recommended dose (RP2D) of the combination. Six-month progression-free survival rate (PFR).", 
                "measure": "Overall response rate (ORR) as determined by RECIST criteria.", 
                "safety_issue": "Yes", 
                "time_frame": "5 years or until disease progression/survival"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hussein Tawbi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}